Leronlimab

{
  "id": "MLC-T-ONC-014751",
  "term": "Leronlimab",
  "field": "Oncology and biomedicine",
  "definition": "A humanized immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5; CD195), with potential activity as a human immunodeficiency virus (HIV) entry blocker and potential protective activity against graft-versus-host disease (GvHD). Upon administration, leronlimab targets and binds to CCR5 expressed on T cells. This blocks HIV cell entry, which prevents HIV infection and/or reduces HIV viral load. In addition, blocking CCR5 by PRO 140 decreases CCR5-mediated signaling and the CCR5-induced migration of donor cells into tissues after an allogeneic hematopoietic cell transplantation (HCT). Blocking CCR5 may therefore prevent or reduce GvHD. CCR5, a co-receptor needed for HIV cell entry, plays a key role in immunomodulation. Expressed on monocytes, activated T cells and dendritic cells (DCs), CCR5 can regulate chemotaxis. Lymphocyte trafficking via chemokine receptors, such as CCR5, and recruitment to target organs, plays a critical role in alloreactive responses.",
  "synonyms": [
    "anti-CCR5 monoclonal antibody PRO 140"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/leronlimab/"
}